Recommended Dose of Injection Pheniramine for Adults
The recommended dose of injection pheniramine for adults is 25-50 mg administered intravenously or intramuscularly. 1
Dosage Guidelines
Pheniramine maleate is an antihistamine commonly used for the treatment of allergic conditions. When administered parenterally, the following dosing recommendations apply:
- Standard adult dose: 25-50 mg per dose 1
- Route of administration: Intravenous (IV) or intramuscular (IM)
- Administration rate: When given IV, should be diluted and infused over 5-10 minutes
- Frequency: Can be repeated as needed based on clinical response and severity of allergic reaction
Clinical Context and Usage
Pheniramine is typically used as a second-line agent in the management of allergic reactions, including:
- Acute allergic reactions
- Urticaria
- Allergic rhinitis
- Pruritus
Role in Anaphylaxis Management
In the context of anaphylaxis management, pheniramine (like other H1 antihistamines) is considered adjunctive therapy to epinephrine:
- Important caveat: H1 antihistamines should never be used alone in the treatment of anaphylaxis 2
- Epinephrine remains the first-line treatment for anaphylaxis
- Pheniramine has a slower onset of action than epinephrine
Monitoring and Precautions
When administering pheniramine injection, monitor for:
- Sedation: Pheniramine can cause significant drowsiness
- Anticholinergic effects: Dry mouth, blurred vision, urinary retention
- Cardiovascular effects: Potential for tachycardia and blood pressure changes
- CNS effects: Dizziness, headache, excitation in some patients
Potential Adverse Effects
Common adverse effects include:
- Drowsiness (most common)
- Dry mouth
- Blurred vision
- Constipation
Serious but rare adverse effects in overdose scenarios:
- Rhabdomyolysis 3, 4
- Acute kidney injury
- Cardiotoxicity (rare but reported) 3
- CNS excitation including seizures
Special Considerations
- Renal impairment: Use with caution as pheniramine overdose has been associated with rhabdomyolysis and acute kidney injury 4
- Elderly patients: Consider lower doses due to increased sensitivity to anticholinergic effects
- Patients with cardiovascular disease: Monitor closely for cardiovascular effects
Comparative Efficacy
In clinical studies, pheniramine has shown efficacy in managing allergic symptoms:
- When used in ophthalmic preparations, pheniramine (in combination with naphazoline) has demonstrated effectiveness in alleviating signs and symptoms of acute ocular allergic reactions 5
- In chronic idiopathic urticaria, oral pheniramine (25 mg twice daily) showed lower efficacy compared to newer antihistamines like loratadine, with higher rates of drowsiness 6
Pharmacokinetics
After intravenous administration:
- Peak serum concentrations: 231-894 ng/ml
- Terminal half-life: 8-17 hours
- Metabolized to N-desmethyl pheniramine and N-didesmethyl pheniramine 7
Remember that pheniramine is a second-line agent for allergic reactions, and epinephrine remains the first-line treatment for anaphylaxis. The injection should be administered carefully with appropriate monitoring for adverse effects.